摘要目的:探讨长链非编码RNA-POU3F3（LncRNA-POU3F3）在甲状腺癌组织中的表达情况及对患者预后的影响。方法:采用病例-对照研究，收集2013年5月至2015年8月在郑州人民医院手术的118例甲状腺癌患者的癌组织和癌旁组织，另选取同时期100例甲状腺良性肿瘤患者的甲状腺良性肿瘤组织作为对照。采用实时荧光定量PCR（qRT-PCR）方法检测甲状腺组织中LncRNA-POU3F3的表达情况，使用受试者工作特征曲线（ROC曲线）评价LncRNA-POU3F3对甲状腺癌的诊断价值，并分析LncRNA-POU3F3表达与患者临床病理特征及预后的相关性。结果:qRT-PCR结果显示，与癌旁组织（3.18 ± 0.69）、甲状腺良性肿瘤组织（3.05 ± 0.66）比较，LncRNA-POU3F3在甲状腺癌组织表达水平（4.02 ± 0.76）较高（ P均< 0.05）。LncRNA-POU3F3表达诊断甲状腺癌ROC曲线下面积为0.886[95%置信区间（95% CI）：0.821 ~ 0.943， P < 0.05]，敏感度为83.7%，特异度为85.2%，诊断阈值为3.45；临床分期为Ⅲ ~ Ⅳ期、肿瘤直径≥1 cm、多发癌灶及伴有淋巴结转移的甲状腺癌组织中LncRNA-POU3F3高表达（≥3.45）比例均较高（ P均< 0.05）；Kaplan-Meier法分析结果显示，随访5年后，纳入的118例甲状腺癌患者存活53例，其中LncRNA-POU3F3低表达者（ < 3.45）5年生存率为77.42%（24/31），LncRNA-POU3F3高表达者（≥3.45）5年生存率为33.33%（29/87），两组5年生存率比较差异有统计学意义（χ 2 = 17.955， P < 0.05）；多因素logistic回归分析显示，临床分期、肿瘤直径、癌灶数量、淋巴结转移和LncRNA-POU3F3表达均与甲状腺癌患者生存期相关（ P均< 0.05）。 结论:LncRNA-POU3F3在甲状腺癌组织中呈高表达，其表达水平与甲状腺癌患者临床病理特征及预后密切相关，可作为预测甲状腺癌患者预后的重要指标。

abstractsObjective:To investigate the expression of long non-coding RNA-POU3F3 (LncRNA-POU3F3) in thyroid cancer tissues and its predictive value for prognosis.Methods:Using case-control study, the thyroid cancer tissue samples and paracancerous tissue samples of 118 thyroid cancer patients who underwent surgery in Zhengzhou People's Hospital from May 2013 to August 2015 were collected, and 100 benign thyroid tumor tissue samples in the same period were selected as controls. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of LncRNA-POU3F3 in thyroid tissues, receiver operating characteristic curve (ROC curve) was used to evaluate the diagnostic value of LncRNA-POU3F3 for thyroid cancer, and the correlation between LncRNA-POU3F3 level and clinicopathological characteristics and prognosis of patients was analyzed.Results:The qRT-PCR results showed that the expression level of LncRNA-POU3F3 in thyroid cancer tissues (4.02 ± 0.76) was higher than that in paracancerous tissues (3.18 ± 0.69) and benign thyroid tumor tissues (3.05 ± 0.66, P < 0.05). The area under the ROC curve of LncRNA-POU3F3 expression in the diagnosis of thyroid cancer was 0.886 [95% confidence interval (95% CI): 0.821 - 0.943, P < 0.05], the sensitivity was 83.7%, the specificity was 85.2%, and the diagnostic threshold was 3.45. High expression of LncRNA-POU3F3 (≥3.45) was found in thyroid cancer tissues with clinical stages Ⅲ - Ⅳ, tumor diameter ≥1 cm, multiple tumor foci and lymph node metastasis ( P < 0.05). Kaplan-Meier analysis showed that after 5 years of follow-up, 53 of the 118 patients with thyroid cancer survived. The 5-year survival rate of patients with low expression of LncRNA-POU3F3 ( < 3.45) was 77.42% (24/31), and that of patients with high expression of LncRNA-POU3F3 (≥3.45) was 33.33% (29/87), and there was a statistically significant difference in the 5-year survival rate between the two groups (χ 2 = 17.955, P < 0.05). Multivariate logistic regression analysis showed that clinical stage, tumor diameter, number of tumor foci, lymph node metastasis and LncRNA-POU3F3 expression were correlated with the survival time of patients with thyroid cancer ( P < 0.05). Conclusion:LncRNA-POU3F3 is highly expressed in thyroid cancer tissues, and its expression level is closely related to the clinicopathological characteristics and prognosis of thyroid cancer patients, which can be used as an important indicator for predicting the prognosis of thyroid cancer patients.